Abstract
Background:Heme Oxygenase-1 (HO-1) is a metabolic enzyme strongly involved in processes including cytoprotection, modulation of inflammatory response, anti-oxidative functions, regulation of cellular proliferation, angiogenesis, cardiovascular homeostasis, and immuno-modulation. HO-1 induction and/or activation is able to counterbalance, at least in part, oxidative stress and inflammation. For this reason, HO-1 can be regarded as an attractive target to ameliorate different stress-related pathologies. Caffeic acid phenethyl ester, a natural polyphenolic compound, behaves as HO-1 inducer and possesses a plethora of beneficial effects under oxidative stress conditions.
Objectives: A small focused series of caffeic acid phenethyl ester (Cape) analogues was designed and synthesized with the aim of obtaining more potent HO-1 inducers. Method: The capacity of these new compounds to modify the levels of HO-1 was evaluated in human mesenchymal stem cells (hMSCs) derived from bone marrow. Results and conclusion: Some of tested compounds were found to be good HO-1 inducers and 3-(3,4- dihydroxyphenyl)-(2E)-2-propenoic acid 2-(3,4-dimethoxyphenyl) ethyl ester (VP961) was the most potent. VP961 tested to measure HO-1 protein expression and HO activity in in vitro system resulted more potent than the parent compound Cape both as inducer and as direct activator of the enzyme. VP961, selected as lead compound for further characterization, showed antioxidant properties in a model of H2O2-mediated ROS production and cytoprotective effects in a model of H2O2 cells viability impairment. To the best of our knowledge, VP961 is the first known compound able to activate directly HO-1 enzyme and to induce at the same time its protein expression.Keywords: Heme oxygenase, HO-1 inducers, caffeic acid phenethyl ester, ROS, human MSCs, VP961.
Current Pharmaceutical Design
Title:Novel Caffeic Acid Phenethyl Ester (Cape) Analogues as Inducers of Heme Oxygenase-1
Volume: 23 Issue: 18
Author(s): Valeria Pittala*, Luca Vanella, Loredana Salerno, Claudia Di Giacomo, Rosaria Acquaviva, Marco Raffaele, Giuseppe Romeo, Maria N. Modica, Orazio Prezzavento and Valeria Sorrenti
Affiliation:
- Department of Drug Sciences, University of Catania, viale A. Doria 6, 95125 Catania,Italy
Keywords: Heme oxygenase, HO-1 inducers, caffeic acid phenethyl ester, ROS, human MSCs, VP961.
Abstract: Background:Heme Oxygenase-1 (HO-1) is a metabolic enzyme strongly involved in processes including cytoprotection, modulation of inflammatory response, anti-oxidative functions, regulation of cellular proliferation, angiogenesis, cardiovascular homeostasis, and immuno-modulation. HO-1 induction and/or activation is able to counterbalance, at least in part, oxidative stress and inflammation. For this reason, HO-1 can be regarded as an attractive target to ameliorate different stress-related pathologies. Caffeic acid phenethyl ester, a natural polyphenolic compound, behaves as HO-1 inducer and possesses a plethora of beneficial effects under oxidative stress conditions.
Objectives: A small focused series of caffeic acid phenethyl ester (Cape) analogues was designed and synthesized with the aim of obtaining more potent HO-1 inducers. Method: The capacity of these new compounds to modify the levels of HO-1 was evaluated in human mesenchymal stem cells (hMSCs) derived from bone marrow. Results and conclusion: Some of tested compounds were found to be good HO-1 inducers and 3-(3,4- dihydroxyphenyl)-(2E)-2-propenoic acid 2-(3,4-dimethoxyphenyl) ethyl ester (VP961) was the most potent. VP961 tested to measure HO-1 protein expression and HO activity in in vitro system resulted more potent than the parent compound Cape both as inducer and as direct activator of the enzyme. VP961, selected as lead compound for further characterization, showed antioxidant properties in a model of H2O2-mediated ROS production and cytoprotective effects in a model of H2O2 cells viability impairment. To the best of our knowledge, VP961 is the first known compound able to activate directly HO-1 enzyme and to induce at the same time its protein expression.Export Options
About this article
Cite this article as:
Pittala Valeria*, Vanella Luca, Salerno Loredana, Di Giacomo Claudia, Acquaviva Rosaria, Raffaele Marco, Romeo Giuseppe, Modica N. Maria, Prezzavento Orazio and Sorrenti Valeria, Novel Caffeic Acid Phenethyl Ester (Cape) Analogues as Inducers of Heme Oxygenase-1, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612823666170210151411
DOI https://dx.doi.org/10.2174/1381612823666170210151411 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of Carotid Stenosis
Current Vascular Pharmacology Amino Thiols, Detoxification and Oxidative Stress in Pre-Eclampsia and Other Disorders of Pregnancy
Current Pharmaceutical Design Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Renin-angiotensin System Blockade at the Level of the Angiotensin Converting Enzyme or the Angiotensin Type-1 Receptor: Similarities and Differences
Current Topics in Medicinal Chemistry Current Treatments of Primary Sclerosing Cholangitis
Current Medicinal Chemistry Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications
Current Topics in Medicinal Chemistry Gastrin-Releasing Peptide Receptor as a Molecular Target for Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Glucose Tolerance Status in Pregnancy: A Window to the Future Risk of Diabetes and Cardiovascular Disease in Young Women
Current Diabetes Reviews Meet Our Editorial Board Member
Current Vascular Pharmacology Modulation of the Immune System for the Treatment of Glaucoma
Current Neuropharmacology Novel Oral Anticoagulants in the Treatment of Acute Coronary Syndromes: Is there any Room for New Anticoagulants?
Current Clinical Pharmacology A Review of the Chemical and Pharmacological Aspects of the Genus Marrubium
Current Pharmaceutical Design Angiogenesis and Angiogenic Inhibitors in Non Small Cell Lung Cancer
Current Angiogenesis (Discontinued) Antithrombotic Options for Atrial Fibrillation in 2012
Cardiovascular & Hematological Disorders-Drug Targets Meet Our Editorial Board Member
Current Hypertension Reviews The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes
Current Vascular Pharmacology Cardioprotection Against Ischemia/Reperfusion Injury and Chromogranin ADerived Peptides
Current Medicinal Chemistry Endocannabinoid Metabolic Pathways and Enzymes
Current Drug Targets - CNS & Neurological Disorders Bioavailability of Quercetin: Problems and Promises
Current Medicinal Chemistry Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology